NFE2L2 and colorectal carcinoma: Taken together, these results provide a novel insight into the molecular chaperone activity of PRDX1 in promoting CRC progression by inhibiting ferroptosis through suppression of CUL3-mediated NRF2 degradation, which will provide a potential drug target for intervention in CRC progression.